LHON/MELAS overlap mutation in ND1 subunit of mitochondrial complex I affects ubiquinone binding as revealed by modeling in Escherichia coli NDH-1  by Pätsi, Jukka et al.
Biochimica et Biophysica Acta 1817 (2012) 312–318
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbabioLHON/MELAS overlap mutation in ND1 subunit of mitochondrial complex I affects
ubiquinone binding as revealed by modeling in Escherichia coli NDH-1
Jukka Pätsi a, Pilvi Maliniemi a, Salla Pakanen b,c,e, Reetta Hinttala d,e, Johanna Uusimaa b,e, Kari Majamaa d,e,
Thomas Nyström f, Marko Kervinen a,c,e,⁎, Ilmo E. Hassinen a,⁎⁎
a Institute of Biomedicine, Department of Medical Biochemistry and Molecular Biology, University of Oulu, P.O. Box 5000, FIN-90014 University of Oulu, Finland
b Institute of Clinical Medicine, Department of Paediatrics, University of Oulu, P.O. Box 5000, FIN-90014 University of Oulu, Finland
c Institute of Clinical Medicine, Department of Ophthalmology, University of Oulu, P.O. Box 5000, FIN-90014 University of Oulu, Finland
d Institute of Clinical Medicine, Department of Neurology, University of Oulu, P.O. Box 5000, FIN-90014 University of Oulu, Finland
e Clinical Research Center, Oulu University Hospital, P.O. Box 5000, FIN-90014 University of Oulu, Finland
f Department of Cell and Molecular Biology, University of Gothenburg, BOX 462, SE-40530 Gothenburg, SwedenAbbreviations: d-NADH, deamino-NADH; DB, decyl
neruthenium; LHON, Leber hereditaryoptic neuropathy;M
encephalopathy, lactic acidosis and stroke-like episodes sy
DNA; NDH-1, bacterial proton pumping NADH-ubiquin
bacterial non-proton pumping NADH-ubiquinone oxid
Q2, ubiquinone-2; UQ, ubiquinone; VNA, N-vanillylnonan
⁎ Correspondence to: M. Kervinen, Department of Oph
Medicine, University of Oulu (visiting address: Clinical Re
Box 5000, FIN-90014 Oulu, Finland. Tel.: +358 8 537630
⁎⁎ Correspondence to: I. Hassinen, Department of Medi
Biology, Institute of Biomedicine, University of Oulu (vis
Box 5000, FIN-90014 Oulu, Finland. Tel.: +358 8 537580
E-mail addresses: marko.kervinen@oulu.ﬁ (M. Kervi
(I.E. Hassinen).
0005-2728/$ – see front matter © 2011 Elsevier B.V. Al
doi:10.1016/j.bbabio.2011.10.014a b s t r a c ta r t i c l e i n f oArticle history:
Received 25 June 2011
Received in revised form 27 October 2011
Accepted 28 October 2011
Available online 4 November 2011
Keywords:
Escherichia coli
Leber hereditary optic neuropathy
MELAS
Mitochondria
NADH-ubiquinone oxidoreductase
UbiquinoneDefects in complex I due to mutations in mitochondrial DNA are associated with clinical features ranging
from single organ manifestation like Leber hereditary optic neuropathy (LHON) to multiorgan disorders
like mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) syndrome.
Speciﬁc mutations cause overlap syndromes combining several phenotypes, but the mechanisms of their
biochemical effects are largely unknown. The m.3376G>A transition leading to p.E24K substitution in
ND1 with LHON/MELAS phenotype was modeled here in a homologous position (NuoH-E36K) in the
Escherichia coli enzyme and it almost totally abolished complex I activity. The more conservative mutation
NuoH-E36Q resulted in higher apparent Km for ubiquinone and diminished inhibitor sensitivity. A NuoH
homolog of the m.3865A>G transition, which has been found concomitantly in the overlap syndrome patient
with the m.3376G>A, had only a minor effect. Consequences of a primary LHON-mutation m.3460G>A
affecting the same extramembrane loop as the m.3376G>A substitution were also studied in the E. coli
model and were found to be mild. The results indicate that the overlap syndrome-associated
m.3376G>A transition in MTND1 is the pathogenic mutation and m.3865A>G transition has minor, if
any, effect on presentation of the disease. The kinetic effects of the NuoH-E36Qmutation suggest its proximity
to the putative ubiquinone binding domain in 49 kD/PSST subunits. In all, m.3376G>A perturbs ubiquinone
binding, a phenomenon found in LHON, and decreases the activity of fully assembled complex I as in MELAS.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
NADH-ubiquinone oxidoreductase (Complex I, EC 1.6.5.3) is by far
the most complicated enzyme of the mitochondrial respiratory chain.
It is composed of 45 different polypeptides and a set of redox centersubiquinone; HAR, hexaammi-
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l rights reserved.resulting in a total molecular mass of about 1000 kDa in mammals [1].
Seven of the complex I subunits (ND1–ND6 and ND4L) are encoded in
mitochondrial genome (mtDNA)while the rest of the genes are located
in the nucleus. Fourteen of the subunits, including all the NDs, have
their homologs in NDH-1, the bacterial counterparts of the enzyme,
and are considered to comprise the catalytic core of complex I (for
a review, see [2]).
Regardless of increasing knowledge of the structure of complex I
[3–6], the number and exact position of ubiquinone binding sites
are still ambiguous. The iron–sulphur cluster N2 in the PSST subunit
is thought to be the ﬁnal electron donor to ubiquinone (UQ). Based on
extensive mutational analysis of the PSST and 49 kD subunit homologs
in Yarrowia lipolytica it has been demonstrated that many conserved
residues lining the cavity between these peptides in the proximity of
N2 are critical for the catalytic activity and inhibitor binding. It has
therefore been suggested that a UQ binding domain is located within
this pocket, although apart from Tyr-144 mutations in 49 kD subunit,
most mutations with appreciable changes in inhibitor sensitivity affect
very little the apparent Km value for UQ [7–11]. A second puzzling
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indicate only partially competitive binding for classical, quinone
site-binding inhibitors like piericidin A. Some others, like rotenone,
show a more mixed (non-competitive) type of inhibition [12], although
all these inhibitors are regarded to bind to separate partially overlapping
sites in the same domain [13].
ND1 as oneof the core subunits in themembrane domain of complex
I is apparently involved in attaching the hydrophilic part of the enzyme
to the membrane [6,14]. Based on the locations of the helices of the
membrane armof the holoenzyme in Thermus thermophilus, an essential
role has been proposed for ND1 in coupling the electron and proton
transfer reactions of complex I [6]. Some evidence points to its involve-
ment in UQ-binding, too. Structure of the membranous domain of
Escherichia coli and T. thermophilusNDH-1 in combinationwith previous
biochemical evidence has revealed a putative ubiquinone entry channel
or binding site in NuoH/Nqo8, which are homologs of themitochondrial
ND1 subunit [6,15].
Complex I dysfunction is a common cause ofmitochondrial disorders
such as mitochondrial myopathy, encephalopathy, lactic acidosis and
stroke-like episodes syndrome (MELAS) and Leber hereditary optic
neuropathy (LHON). At least 33 disease-associated substitutions have
been reported so far in the MTND1 gene (Mitomap, available from
http://mitomap.org/MITOMAP, on April 14th 2011) emphasizing the
importance of ND1 in complex I function. Similarly to the common
m.3243A>G MELAS mutation [16–18], a decrease in amount of active
complex I or its stability has been reported in transmitochondrial cybrid
cell lines derived from patient ﬁbroblasts and in bacterial models
displaying ND1-subunit MELAS mutations [19–21]. In the case of
ND1-affecting m.3460G>A mutation, one of the primary mutations
associated with non-syndromic LHON, the in vitro electron transfer
activity of the enzyme complex is strongly reduced and resistance
to rotenone has been documented (for a review, see e.g. [22]).MTND1
is a target for less common disease-associated mtDNA mutations as
well. A potentially pathogenic, heteroplasmic m.3376G>A mutation
in MTND1 has been discovered in a patient suffering from the LHON/
MELAS overlap syndrome [23]. The proband carried also an
m.3865A>G transition affecting the same subunit, but it was not
considered to be pathogenic since it was also present in the unaffected
mother of the proband. In skeletal muscle, the citrate synthase-Fig. 1. The ﬁrst and the third inside loops of human ND1 and E. coli NuoH with parts of borde
the corresponding amino acid changes p.E24K (m.3376G>A) [23], p.R25Q (m.3380G>A) [53
p.E59K (m.3481G>A) [21,58] and p.I187V (m.3865A>G) [23] are indicated. The residues u
alignment of homologous complex I subunits from human (GenBank ID: AEO90223.1), bo
O47868), E. coli (GenBank: AAC75342.1) and P. denitriﬁcans (GenBank ID: AAA25592.1) wa
TMHMM program [40]. “t” denotes transmembrane helix and “i” inside loop. The 70% consensu
sequences.normalized complex I activity was 36% of control [23]. Effects of
this mutation on complex I have not been scrutinized any further.
Interestingly, the m.3376G>A transition results in replacement of the
highly conserved glutamate residue (Glu-24) by lysine in ND1 in an
extramembranous loop, which is also a target of the common
m.3460G>A LHON mutation as well as many other disease-associated
substitutions (see Fig. 1).
The m.3376G>A mutation does not fulﬁll all the commonly
accepted criteria for a pathogenic mtDNA mutation [24] and also
the role of the m.3865A>G transition in the formation of the disease
phenotype has remained unproven. We show here by employing an
E. coli model that m.3376G>A mutation is clearly pathogenic,
whereas m.3865A>G has only minor, if any, effect. Interestingly,
m.3376G>A decreases enzyme amount similarly to other MELAS
mutations affecting the same gene [19] and also disturbs theubiquinone
binding domain, which has been previously shown to be associatedwith
LHON mutations [22,25,26]. To our knowledge, this is the ﬁrst time the
biochemical consequences of an mtDNA mutation associated with an
LHON/MELAS overlap syndrome is analyzed on a stable, bacterial
application framework. Because of the relative paucity of the
mtDNA mutations, their metabolic link to human disease is difﬁcult
to conﬁrm on basis of biopsy samples. Therefore, their investigation
by means of site-directed mutagenesis in bacterial models is gaining
increasing practice, exempliﬁed by studies on LHON, [25–28] and
MELAS [19]. Although limited to the structural genes of the core
subunits and to the effects at enzymatic level, a bacterial model for
an mtDNAmutation enables introduction of mutations not occurring
naturally, to better analyze the consequences of a single amino acid
substitution.
2. Materials and methods
2.1. Chemicals
Decylubiquinone (DB), ubiquinone-1 (Q1), ubiquinone-2 (Q2), NADH,
deamino-NADH (d-NADH), DL-malate, N-vanillylnonanamide (VNA),
soya bean phospholipids (Asolectin) and p-Nitro-Blue tetrazolium
chloride (NBT) were from Sigma. Hexaammineruthenium (HAR) was
purchased from Aldrich, Hepes and Mes from AppliChem, andring transmembrane helices 1 and 2, 5 and 6. Disease-associated mtDNAmutations and
], p.Y30H (m.3394T>C) [54,55], p.M31V (m.3397A>G) [56], p.A52T (m.3460G>A) [57],
ndergoing site-directed mutagenesis are shown in white font on black background. An
vine (GenBank ID: ADF49509.1), carp (NCBI ID: NP_007082.1), alligator (UniProt ID:
s performed by means of ClustalW, and the transmembrane topology by means of the
s sequence was compiled by the PredictProt server from an alignment of 186 homologous
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Fluka. Oligonucleotides were purchased from Sigma-Genosys or
Oligomer. The QuikChange® XL mutagenesis kit was from Stratagene,
BCA kit from Pierce and Phusion DNA polymerase from Finnzymes.
Bis–Tris gradient gels for Blue native electrophoresis were from
Invitrogen. An annonaceous acetogenin mixture (Annona squamosa
seed extract) was a generous gift from Dr. Y. K. Gupta, Varanasi,
India. Stigmatellin was from Sigma except for the inhibition type
analysis, wherein it was kindly provided by Professor U. Brandt,
Frankfurt am Main, Germany.
2.2. Site-directed mutagenesis and NuoH expression
NuoH point mutations listed in Table 1 were introduced into an
expression plasmid pHwt carrying the wild type nuoH under a T7
lac promoter as previously described [19]. The oligonucleotides used
in mutagenesis are listed in Supplementary Table S1. Correctness of
the constructs was veriﬁed by DNA sequencing of the mutant gene.
In-trans complementation of the nuoH deletion was done by trans-
forming a nuoH knock-out derivative (HK18) of E. coli strain GV102
[19] with plasmids expressing either wild type or mutated nuoH.
To evaluate the performance of the in-trans complementation system,
genomic complementation of the nuoH-E36Q mutant allele was
accomplished as follows. The recipient strain for mutant allele
was prepared from MG1655 wild type laboratory strain by deleting
the whole nuoH gene and replacing it with a Zeocin resistance gene
according to [19] except that the ZeoR gene was used instead of the
SmR gene in the deletion construct according to [29]. For the mutant
allele, Nhe1–Xho1 restriction sites were introduced in front of the
streptomycin resistance gene in pLitmus39 containing nuoH ﬂanking
regionswith streptomycin resistance gene in betweenUF+Sm+LF [19]
by QuikChange® XL mutagenesis kit according to the manufacturer's
instructions and oligonucleotides GstopF and GstopR listed in
Supplementary Table S1. The ﬂanking regions were sequenced in
order to exclude unintentional mutations in the construct. Nhe1-Sal1
fragment containing thewhole nuoH gene fromNuoH-E36Q expression
plasmid was cloned into the Nhe1–Xho1 site in pLitmus39-UF+Sm+
LF. Sal1-Stu1 fragment from this plasmid was used to transform
JW2277(ΔnuoH::kan) strain [30] expressing phage λ Red recombinase
from pKD46 plasmid [31]. A streptomycin resistant and kanamycin
sensitive colony was selected and the mutant allele was transferred
to the recipient strain (MG1655 ΔnuoH::Zeo described earlier) by
standard P1 transduction and selected for streptomycin resistance.
The correct strain was veriﬁed by loss of Zeocin resistance and PCR.
In order to obtain the same composition of E. coli respiratory chain as
in plasmid complementation strains, Δcyo::kan allele was transferred
from GV102 into MG1655 (resulting in MKG311 strain, used as a
control) and into NuoH-E36Q strain (MKGnuoH36-31 strain).
TheMKG51-32 strain lacking the whole nuo operonwas generated
as follows. BW25113 strain [31] expressing phage λ Red recombinase
from pKD46 plasmid was transformed with PCR product containing
recombination sequences up- and downstream of nuo genes according
to [32] with chloramphenicol resistance marker in between ampliﬁed
from pKD3 plasmid [31]. The deletion and Δcyo::kan alleles wereTable 1
Mutations introduced into the NuoH subunit of Escherichia coliNDH-1 and corresponding
disease-associated substitutions in the ND1 subunit of mitochondrial complex I.
Mitochondrial mutation in ND1 subunit gene Mutations
introduced into
E. coli NuoH
Nucleotide
change
Amino acid
change
Resulting
disease
Reference
m.3376G>A/
m.3865A>G
E24K/I187V LHON/MELAS [23] E36K, E36Q,
E36D
I201V
m.3460G>A A52T LHON [57] M64T
Not applicable D63Etransferred into MG1655 by P1 transduction as stated earlier. The
resulting strain was veriﬁed for the loss of nuo operon by PCR
and absence of d-NADH oxidation and HAR reductase capacities.
2.3. Bacterial growth and membrane preparation
Bacteria were routinely grown in LB medium supplemented with
appropriate antibiotics. Collection of cells and preparation of membrane
sampleswere performed as described before [19]. Protein concentrations
of the membrane samples were determined according to Lowry [33] or
by BCA kit from Pierce.
2.4. Enzyme activity measurements and inhibitor sensitivity tests
E. coli and some other bacteria express two NADH-ubiquinone
oxidoreductases, NDH-1 and NDH-2. The former is a homolog of
complex I and is capable of oxidizing both d-NADH and NADH, while
the single subunit, non-proton pumping NDH-2 puriﬁed from E. coli
is able to oxidize only NADH [34]. Therefore, d-NADH was used
instead of NADH throughout this study to measure NDH-1-dependent
activities.
d-NADH:DB, d-NADH:Q1, d-NADH:Q2, d-NADH:O2, d-NADH:HAR
and NADH:O2 oxidoreductase activities in cytoplasmic membranes
were assayed spectrophotometrically as described by us earlier [19].
Sensitivity of d-NADH:DB activity to piericidin A, stigmatellin, VNA
and annonaceous acetogenins was tested as previously [25]. Curve
ﬁtting to a kinetic equation was performed with Sigmaplot 9.0
(Systat Software, Erkrath, Germany). Enzyme activities or inhibitor
sensitivities of the mutants and control in the present study are
measured from in-trans complemented strains if not otherwise
speciﬁed.
To determine the inhibition type of piericidinA, VNAand stigmatellin,
d-NADH:DB activity was assayed basically as described earlier. Initial
velocities were measured with 52, 100 and 200 μM DB and reaction
progress curves run with 25 μM or 41 μM initial DB concentration in
the absence and presence of an inhibitor. 50 and 150 μM VNA, 9, 18
and 36 μM piericidin A or 5, 10, 20 and 33 μM stigmatellin were used
to inhibit the NDH-1 activity, and control reactions without inhibitors
were run in the presence of equal volume of ethanol used as a solvent
for the inhibitors. Global ﬁt of the data to the general equation
v=Vmax·[S]/{Km·(1+[i]/Kic)+[S]·(1+[i]/Kiu)} for mixed inhibition
[35] was performed for each of the inhibitors with non-linear regression
in Microsoft Excel to solve the inhibitor constants for free enzyme (Kic)
and the enzyme–substrate complex (Kiu). Concentration of the ethanol
stock solution of stigmatellin used for the analysis of its inhibition type
was determined spectrophotometrically by measuring its absorbance at
270 nm in 50 mM potassium phosphate buffer, pH 7.4, and using an
extinction coefﬁcient 48.9 mM−1 cm−1 calculated from the data
presented by Gerencsér and co-workers [36].
2.5. Analytical methods
To investigate the assembly of NDH-1 in the E36Q mutant
produced by genomic complementation, proteins from cytoplasmic
membranes were solubilized with 0.2% n-dodecyl-β-D-maltoside in
ε-aminocaproate Bis–Tris buffer as described earlier [37]. Subsequent
Blue native PAGE (BN-PAGE) was performed in 3 to 12% Novex
NativePAGE Bis–Tris 8 cm×8 cmgel (Invitrogen) essentially according
to Schägger [38], followed by staining with NADH and p-nitro blue
tetrazolium [14].
2.6. Statistical methods
Student's t test for independent samples was used to compare two
groups. For multiple comparisons of the statistical signiﬁcance between
differentmutants or control, one-wayANOVA followed by theDunnett's
Mutant
Contr E36K E36Q E36D D63E M64T I201V
0
100
200
300
400
500
600 dNADH O2
NADH O2
dNADH HAR
***
***
*
***
**
**
**
*
*
***
Ac
tiv
ity
 (n
mo
l·m
in-
1 ·
m
g-
1  
pr
ot
.)
Fig. 2. Respiratory activities in NuoH mutants and control. HAR reductase activity is
13.0±0.2 nmol min−1 mg−1 prot in the nuo operon deletion strain. The values are
means±S.D from two to nineteen independent membrane preparations. *pb0.05,
**pb0.01, ***pb0.001.
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or the PredictProtein server (http://www.predictprotein.org/), the
conservation scores with the Scorecons server (http://www.ebi.ac.uk/
thornton-srv/databases/cgi-bin/valdar/scorecons_server.pl), and trans-
membrane topology by means of the TMHMM program (http://www.
cbs.dtu.dk/services/TMHMM/) [40].
3. Results
3.1. NuoH effects of mutations corresponding to the LHON/MELAS overlap
syndrome-associated m.3376G>A and m.3865A>G
The m.3376G>A and m.3865A>G transitions in human lead to p.
E24K and p.I187V substitutions in ND1. Corresponding residues in the
homologous NuoH subunit of E. coli are Glu-36 and Ile-201 (Fig. 1).
Replacement of the evolutionally conserved residue Glu-36 with ly-
sine in E. coli NuoH had a drastic effect on NDH-1 activity. The d-
NADH:DB oxidoreductase activity (at 100 μM DB) in
membranes from the E36K mutant was almost totally abolished
(Table 2) and could not be enhanced by increasing theDB concentration
(data not shown) preventing further analysis of the effects of this
mutation on NDH-1 function. The mutation effect was similar
when Q2 or Q1 was the substrate, although the latter showed slight
increase of NDH-1 activity with increasing Q1 concentration, but
this was not different from the nuoH deletion strain (data not
shown). Interestingly, the d-NADH:O2 activity, which utilizes
endogenous UQ, was more severely affected than the d-NADH:UQ
reductase activity with short-chained DB, presenting 4% and 13% of
control activities (all normalized for enzyme amount), respectively
(Table 2). Also the d-NADH:HAR reductase activity was decreased,
suggesting a decrease in the amount of fully assembled NDH-1 in
cytoplasmic membranes (Fig. 2).
The I201V substitution, analogous to human p.I187V, had a small
effect on the amount of NDH-1 in the membranes but the activity
with DB or the apparent Km for DB were not markedly decreased
(Fig. 2 and Table 2).
3.2. Glu-36 residue of NuoH subunit in E. coli NDH-1 contributes to
ubiquinone binding
Since the E36K mutant was devoid of NDH-1 activity, more
conservative changes were tested by replacing Glu-36 with aspartate
or glutamine. Replacement of the glutamate side chain with the
amido group-bearing glutamine decreased the d-NADH:O2 and
d-NADH:DB activities to about 32% of controls when normalized for
the amount of enzyme in the membrane (Table 2). Using Q1 instead of
DB showed a less severe loss of NDH-1 activity, the Vmax/HAR
reductase-ratio being about 74% of control (0.431 vs0.581 in themutant
and control, respectively). Surprisingly, the E36Q mutant also showed
decreased afﬁnity to DB (Table 2), and the apparent Km for Q1 wasTable 2
Analysis of d-NADH:UQ oxidoreductase activity with DB (d-NADH→DB) and endogenous u
E36D, D63E, M64T and I201V.
Activity at 100 μM DB and Vmax as well as d-NADH→O2 activity were normalized to d-NAD
numbers in parenthesis indicate the number of independent membrane preparations analy
Mutation d-NADH→DB at 90 μM d-NADH and 100 μM DB
nmol min−1 mg−1 DB/HAR reductase-ratio
Control 184±32 (14) 0.456±0.053 (14)
E36K 12±2 (3)a 0.057±0.013 (3)a
E36Q 34±10 (4)a 0.147±0.035 (4)a
E36D 106±22 (3)b 0.414±0.084 (3)
D63E 65±29 (6)a 0.357±0.051 (6)b
M64T 166±36 (5) 0.392±0.032 (5)
I201V 124±24 (2) 0.481±0.054 (2)
apb0.001; bpb0.01; cpb0.05; dn.a., not applicable.almost 4-fold higher, being 151 μM in E36Q and 42 μM in the control.
To evaluate this change in UQ interaction with NDH-1 in more detail,
sensitivity towards various complex I inhibitors acting at or near the
UQ binding site(s) was also tested for the E36Q mutant and control.
Congruent with changes in apparent Km for UQ, the E36Q mutant was
found more resistant to piericidin-A, stigmatellin and annonaceous
acetogenins but not to VNA (Table 3). These ﬁndings of the effects of
the in-trans complemented E36Q mutant on inhibitor sensitivity and
kinetic parameters were veriﬁed by introducing the E36Q mutation
to the original position in nuo-operon. As with complementation in
trans, the chromosomal mutation affected the apparent Km for DB to
similar extent (133±4 μM in the E36Q strain and 38±13 μM in the
control strain). In the chromosomal E36Q mutant the I50 value for
piericidin A was 16 μM and 13 μM in the control.
In the case of the genomic E36Q mutant, the amount or activity of
the assembled NDH-1 in the membranes was evaluated by means of
BN-PAGE followed by NADH:nitro blue tetrazolium reductase activity
staining using nuo-operon knock-out to conﬁrm the identity of the
observed NDH-1 band. The results were in accord with the d-NADH:
HAR reductase activity (see Fig. 2), indicating that these shortcut
activities migrate with the assembled enzyme (Fig. 3).
Replacement of glutamate-36 with the less bulky aspartate was
better tolerated than the loss of the acidic group by the E36Qmutation.
When normalized for the amount of the enzyme in themembranes, the
d-NADH:DB activity in the E36Dmutant was normal as well as was the
DB binding afﬁnity (Table 2). Nevertheless, despite the normal DB
reductase moiety in E36D, its d-NADH:O2 activity was slightly reduced
(Table 2 and Fig. 2).biquinone (d-NADH→O2) as a UQ-substrate in control and NuoH-mutants E36K, E36Q,
H→HAR activities to account for variation in expression level. Values are means±S.D.,
zed.
Km for DB Vmax/HAR
reductase
d-NADH→O2/HAR
reductase-ratio
(μM)
38±13 (12) 0.642±0.042 (12) 0.398±0.093 (14)
n.a.d n.a. 0.014±0.004 (3)a
182±97 (3) a 0.386±0.087 (3)a 0.123±0.036 (5)a
38±17 (3) 0.564±0.077 (3) 0.341±0.038 (3)
17±6 (3) 0.429±0.107 (3)a 0.292±0.025 (4)c
43±12 (5) 0.562±0.072 (5) 0.281±0.033 (5)c
29±7 (5) 0.628±0.016 (2) 0.407±0.062 (2)
Table 3
Inhibitor sensitivity of control and NuoH-E36Q mutant NDH-1. I50, the inhibitor
concentration that produced 50% inhibition of the d-NADH:DB activity, was measured
for each of the inhibitors at 100 μM DB. Values are means±S.D, numbers in parenthesis
indicate the number of independent membrane preparations analysed.
I50
Control NuoH-E36Q
VNA (μM) 52±10 (3) 34±1 (2)
Acetogenins a (μg/ml) 0.51±0.06 (2) 1.41±0.22 (2)b
Piericidin A (μM) 8±1 (2) 12±0.05 (2)b
Stigmatellin (μM) 13±2 (3) 44±14 (3)b
a Annona squamosa extract.
b pb0.05.
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with non-syndromic LHON
The amino acid residue affected by the LHON-associated
m.3460G>A mutation (Ala-52 in ND1) is located within the same
extramembrane loop as the one affected by the overlap syndrome
mutation m.3376G>A, and although this residue is not conserved
in E. coli, mutagenesis of the equivalent residue Met-64 in NuoH
was included in the present work. The M64T mutation decreased
the d-NADH:O2 but not the d-NADH:DB reductase activity when
normalized for the amount of NDH-1 in the membrane preparation
(Table 2). However, there was some tendency towards reduced
Vmax/HAR reductase ratio (87% of control) in d-NADH:DB
oxidoreductase activity, but this difference was not statistically
signiﬁcant (Table 2). Moreover, afﬁnity to DB was not affected by
the M64T mutation. Because it has previously been shown that the
mitochondrial p.A52T mutation carrying complex I displays
substrate inhibition by different UQ analogs [41], the NADH-
ubiquinone reductase activity of M64T mutant E. coli NDH-1 was
also tested for substrate inhibition. Titration of the d-NADH:DB
reductase activity within the 0.5–400 μM DB concentration range
did not, however, reveal any tendency for substrate inhibition by
DB in the M64T mutant, nor was it observed in any other E. coli
mutations listed in Table 1 (data not shown).
Although the effects of M64T substitution were mild, mutagenesis
of the adjacent highly conserved Asp-63 residue had more drastic
effects on NDH-1 activity. Replacement of this aspartate with a
more bulky glutamate resulted in decreased d-NADH:HAR reductase
activity (Fig. 2), indicative of a reduction in the amount of NDH-1 in
the membranes. The HAR reductase-normalized Vmax of d-NADH:DB
reductase was only 78% of that in controls and the d-NADH:O2 activity
was similarly affected (Table 2). Because a homologous substitution inFig. 3. Blue native PAGE of dodecyl maltoside-solubilized Escherichia coli membrane
proteins decorated with NADH:nitro blue tetrazolium reductase staining. A nuo operon
knockout strain was used to determine NDH-1 mobility in the gel. (wt) wild type,
(E36Q) genomic NuoH-E36Qmutant, (Δnuo) nuo operon knockout. The arrow indicates
the position of NDH-1-speciﬁc band. 2 μg protein was placed in each well.Paracoccus denitriﬁcans results in substrate inhibition of the d-NADH:
Q2 activity by Q2 [26] this was also tested in the D63E. Indeed,
substrate inhibition by Q2 at concentrations above 200 μM was
observed in the E. coliD63Emutant, but the samephenomenonoccurred
also in controls (data not shown). However, some change in the UQ
binding properties of D63E mutant enzyme did occur, as the apparent
Km for DB was only about half of that in the control (Table 2).
3.4. Intactness of the respiratory chain downstream of NDH-1 in the
NuoH mutants
Some of the mutants analyzed here displayed reduced NADH:O2
activities (Fig. 2) alongside the changes described earlier. To test
whether this was due to NDH-1 defect only or if there were defects
in other parts of the respiratory chain, d-NADH:O2 activities were
subtracted from those with NADH as a substrate. This gives an estimate
of the NDH-2 linked activity bypassing the NDH-1 coupling site. Fig. 2
shows that NDH-2 accounts for 62% of the total NADH oxidation in
the controls and that the absolute contribution of NDH-2 to NADH
respiration is not signiﬁcantly affected by the mutations studied,
demonstrating that the respiratory complexes on the oxygen side of
NDH-1 were functioning normally.
3.5. Effect of added phospholipids on ubiquinone kinetics
Effects of added phospholipids on d-NADH:DB oxidoreductase
were also tested, since in an earlier work [14] the apparent Km for
DB without phospholipids was lower by one order of magnitude
than reported here, although no change in Km for DB has been
observed for isolated E. coli complex I when phospholipids are
omitted from the assay [42]. Unexpectedly, plotting reaction velocity
against substrate concentration during reaction progress in the
absence of sonicated phospholipids showed that d-NADH:DB activity
followed sigmoidal kinetics, which was probably due to inhibition
of the enzymeby reducedDB, since changing the initial DB concentration
resulted in a pattern suggestive of product inhibition (data not shown).
Nevertheless, the apparent Km value for DB in the absence of extra
phospholipids (1.2±1.0 μM,n=2),was in the range observedpreviously
by Sinha and co-workers [14], when calculated from the initial reaction
velocities, validating that our membrane preparation method does not
disturb the ubiquinone binding domain.
3.6. Type of inhibition by piericidin A, VNA and stigmatellin
Since the E36Q mutant showed decreased DB afﬁnity and loss of
inhibitor sensitivity, we also set out to test the type of inhibition for
piericidin A, VNA and stigmatellin in our experimental conditions.
As shown in Supplementary Fig. S1, all three showed a mixed
(non-competitive) pattern of inhibition. The inhibitor constants
(competitive/uncompetitive component) were 17/66, 118/92 and
30/40 μM for piericidin A, VNA and stigmatellin, respectively. Global
ﬁts to the inhibitor data are presented in a Supplementary Fig. S1.
4. Discussion
We used here E. coli as a model organism to investigate the bio-
chemical effects of the respiratory chain complex I subunit ND1-
affecting mutation m.3376G>A. The mutation is associated with the
LHON/MELAS overlap syndrome, but is classiﬁed as probably pathogenic
only [23,43]. In a patient case, mutation heteroplasmy for this mutation
has been reported as 18%, 67% and 98% in blood, epithelium andmuscle,
respectively, and in the latter complex I activity was 36% of normal [23].
When we introduced the corresponding mutation into E. coli NDH-1,
where it causes a NuoH-E36K replacement homologous to the
mitochondrial p.E24K substitution, it led to a 93% loss of enzyme
activity. However, it must be borne in mind that the bacterium was
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render the bacterium more sensitive to it. The NuoH-E36 residue
modiﬁcation was also found to affect UQ and inhibitor binding by
NDH-1. The results presented here about the biochemical consequences
of the glu-36 mutations in E. coli strongly argue for the pathogenicity of
the m.3376G>A mutation. Moreover, the E. coli equivalent of the
mitochondrial 3865A>G mutation had less severe effects than
the substitution corresponding to m.3376G>A. An m.3866T>C
polymorphism has been previously found in a patient with complex
I deﬁciency, and it affects the same amino acid (isoleucine-187) as
m.3865A>G but causes a less conservative substitution of isoleucine
with threonine. Modeling in E. coli has shown that its biochemical con-
sequences are only mild [44], which is in accord with the ﬁndings with
the adjacent m.3865A>G mutation in the present study. Therefore, it
can be concluded that m.3376G>A contributes to the disease develop-
ment more than m.3865A>G, as suggested previously [23].
TheNuoHmutations analyzed in the present studyprovide important
evidence of the UQ binding domain of complex I. Mutations in E. coli
NuoH-E36 decreased the apparent afﬁnity of the enzyme to ubiquinone
and to partially competitive type-A inhibitors and also induce resistance
to stigmatellin, an inhibitor of a less competitive class. In Y. lipolytica,
mutations in 49kD-Y144 cause similar effects [8]. This suggests that
the aforementioned amino acid residues in two different subunits are
located in the same functional ubiquinone binding domain of the
enzyme. Contrary to the Y. lipolytica 49kD-Y144 mutations, in the
present study the E. coli NuoH-E36Q mutation affects the kinetics
of all tested UQ species. It also affects UQ and inhibitor binding to
similar extent. Although an amino acid with a free carboxyl group
seems important at position 36 in NuoH, the interaction of E36
with UQ appears not to be strictly spatially conﬁned, as the shorter
side-chained aspartate in this position was functional in terms of
enzyme activity and afﬁnity for short-chained DB.
Recent work by Sinha and coworkers [14] demonstrates that
many conserved residues within the matrix-side loops of ND1 are
essential for the attachment of the peripheral arm to the membrane
domain of complex I, but no signiﬁcant change in UQ-binding was
observed in any of their mutants. One difference between that
study and ours is that we routinely use externally added sonicated
phospholipids in our kinetic assays, a procedure that was found
advantageous in our previous experimentation on P. denitriﬁcans
membranes to enhance reproducibility [26,45]. Phospholipids are
known to stabilize and activate isolated complex I of both mammalian
and bacterial origin [42,46–48]. They can also diminish the potentially
confounding effect of different amount of native lipid in activity assays.
For these reasons, we used phospholipids in kinetic assays although
they were performed on membrane-attached NDH-1. Added phospho-
lipids affected the apparent Km for DB, but their use in the assaymixture
seemed tobe indispensible since they diminished the product inhibition
characteristics presented by the d-NADH:DB activity progress curves.
The phospholipid effect is most likely due to a solvent effect, which
increases the distribution volume of quinone/quinol, thereby resulting
in an increase in the apparent Km. Added phospholipids may also
attenuate the product inhibition by facilitating the exchange of quinone
and quinol at the active site. One should also note that we interpret the
present experiments by comparing the effects of mutations, so that the
dilution effect of phospholipids cancels out.
Although being somewhat different from data presented by Sinha
et al. [14], our ﬁndings are consistent with other observations pointing
to the involvement of the ﬁrst matrix side loop of ND1 in ubiquinone
binding. In a patient displaying complex I deﬁciency an m.3460G>A
mutation leading to anA52T replacement in the same extramembranous
loop as the m.3376G>A transition has been found. It causes rotenone
insensitivity [49] and affects UQ interaction with enzyme in human
cell lines [41] and also when modeled in P. denitriﬁcans [26]. An E.
coli mutation corresponding to the m.3460G>A substitution was also
generated in our present work. The E. coli equivalent, namely M64T,caused only a slight but not statistically signiﬁcant reduction of
NDH-1 activity. As in P. denitriﬁcans [26], effects of the adjacent D63E
mutation in E. coli were found more deleterious than those of M64T.
These unexpected consequences of the m.3460G>A mutation in E.
coli may be due to differences between the mammalian and bacterial
complex I [45]. Moreover, the position corresponding to human Ala-52
is occupied by a larger methionine residue in the E. coli NuoH subunit,
and there is some variation between species, i.e. the site involved is not
fully conserved (Fig. 1) in contrast to the neighboring aspartate.
We showhere in E. coli that amutation equivalent to them.3376G>A
substitution associated with LHON/MELAS overlap syndrome pro-
duces a biochemical defect of similar magnitude to that commonly
observed with MELAS mutations. Three-to-four-fold increased appar-
ent Km for ubiquinones in the NuoH-E36Q mutant and resistance to
the type A inhibitors piericidin A and annonins, which bind at or near
the UQ binding domain [2,50], suggest that also NuoH-E36K interferes
with UQ binding. Piericidin A, VNA and stigmatellin, were found to be
mixed type of inhibitors, which is in accord to the view that the domain
responsible for substrate and inhibitor-binding is relatively spacious.
It thus appears as if a single LHON/MELAS overlap mutation is able
to disturb UQ interaction as found in LHON and strongly decreases the
catalytic capacity as observed in MELAS, so that the resulting bacterial
phenotype represents an overlap syndrome. If this reﬂects in vivo
situation in patients, these two diseases should be considered to
arise through different pathogenic mechanisms, although they affect
the same enzyme. This view is strengthened by the facts that LHON-like
optic neuropathy is less frequently observed in the conjunction of the
more severe mutations in terms of enzyme activity decrease, MELAS
and Leigh's disease, and that the disease phenotypes associated with
complex I affections are indeed linked to speciﬁc mutations [51,52].
In conclusion, pathogenicity of the LHON/MELAS overlap
syndrome-associated m.3376G>A replacement is corroborated by
homologous mutagenesis of E. coli NuoH. However, the bacterial
counterpart of the m.3865A>G transition, which targets a putative
transmembrane helix in the same subunit and has been observed to
occur concomitantly with the m.3376G>A substitution, was without
a major effect. We propose that residue Glu-36 in the ﬁrst matrix side
loop of NuoH subunit is involved in quinone binding by NDH-1, since
its replacement by glutamine lead to decreased UQ binding afﬁnity
and inhibitor resistance.
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